About Us | Contact Us |        

Fundamentals of Adherence Recovery and the Role of LAIs in Schizophrenia

Psychiatry
Curriculum:
Adherence, Recovery, and the Role of LAIs in Schizophrenia
Credits:
0.75 AMA PRA Category 1 Credit(s)™
Launch Date:
December 23, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Psychiatrists

Relevant Terms:

Adherence, Long-Acting Injectable, Recovery, Schizophrenia

Christoph U. Correll, MD

Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Hofstra North Shore - LIJ School of Medicine
Medical Director of Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital
Glen Oaks, NY

Christoph U. Correll, MD, is professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, both in New York. He is further the director of the Adverse Events Unit and the Core Laboratory Unit at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research. 
 
Professor Correll completed his medical studies at the Free University of Berlin and Dundee University Medical School in Scotland. He is a board certified general psychiatrist and child and adolescent psychiatrist, having trained at The Zucker Hillside Hospital in Queens, New York.
 
Professor Correll's research and clinical work focus on the identification, characterization and treatment of adults and youth with severe psychiatric disorders. His areas of expertise include severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders, including the prodrome, first episode, multi-episode and refractory illness phase. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
 
Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of nine scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

John M. Kane, MD

John M. Kane, MD
Professor of Psychiatry
Hofstra North Shore - LIJ Health System School of Medicine
Vice President
Behavioral Health Services of the North Shore - LIJ Health System
Chairman of Department of Psychiatry and Chief of Staff
The Zucker Hillside Hospital
Glen Oaks, New York

John M. Kane, MD, is Vice President for Behavioral Health Services at North Shore University Hospital of the Long Island Jewish Heath System and he is Chairman of the Department of Psychiatry and Chief of Staff at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane is also a professor of psychiatry, neuroscience, and neurology and the Dr. E. Richard Feinberg Chair in Schizophrenia Research at Albert Einstein College of Medicine in New York, New York as well as Professor and Chair, Department of Psychiatry and the Department of Molecular Medicine at Hofstra North Shore-LIJ School of Medicine.

Dr. Kane is a graduate of Cornell University. He received his medical degree from New York University and completed graduate coursework at Columbia University. He completed his internship and psychiatric residency at Hillside Hospital in Glen Oaks, New York.

Dr. Kane is President of the Psychiatry Research Society, the Schizophrenia International Research Society, the Schizophrenia International Research Society, and the American Society of Clinical Psychopharmacology. He is the program co-chair of the NIMH-ASCP Annual NCDEU New Research Approaches to Mental Health Interventions meeting and a fellow of The New York Academy of Medicine, as well as a member of the board of directors of the American Society of Clinical Psychopharmacology and of the board of trustees for the Association for Research in Nervous and Mental Disease.

Dr. Kane has been a consultant for the National Institute of Mental Health and the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration, and either principle investigator or co-investigator on over 20 studies funded by the National Institute of Mental Health. He has served on the editorial boards of been a reviewer of more than 10 journals and peer-reviewed publications. Dr. Kane has authored 7 books and over 60 book chapters on psychiatry, schizophrenia, and anti-psychotic treatment and over 470 articles in psychiatric publications.

John Lauriello, MD

John Lauriello, MD
Chancellor's Chair of Excellence in Psychiatry
Medical Director of the Missouri Psychiatric Center

Columbia, MO

In June 2009, Dr. Lauriello became only the third permanent chair of the University of Missouri Department of Psychiatry in its 50 year history. Dr. Lauriello holds the University of Missouri Chancellor's Chair of Excellence in Psychiatry. Under his leadership he has overseen the opening of the University of Missouri Psychiatric Center; formerly an acute care state facility it is widely regarded as the psychiatric center of excellence for the Mid Missouri region.
 
Prior to coming to the University of Missouri, Dr. Lauriello was the clinical Vice Chair at the University of New Mexico and Executive Medical Director of the UNM Psychiatric Center. At UNM he directed the Schizophrenia Research Group, which focused on clinical trials and neuroimaging, and served as a UNM site principal investigator for the Mental Illness and Neuroscience Discovery (MIND) Institute, a consortium of universities, schools of medicine, brain research institutions and laboratories in Minnesota, Massachusetts and New Mexico.  
 
Dr. Lauriello remains an active expert and investigator in the area of diagnosis and treatment of schizophrenia. He is an author of over 80 publications and is a frequent presenter at national meetings. His recent awards include the 2011 Drs. M. Page and Henry Laughlin Alumnus of the Year Award, the highest alumni honor presented by the Temple University School of Medicine, and had been voted one of the Best Doctors in America® from 1998 to 2013.

A graduate of Yale University in New Haven, CT, Dr. Lauriello completed medical school at Temple University in Philadelphia and residency at New York Presbyterian Hospital's Payne Whitney Psychiatric Clinic. He completed fellowships focused on psychopharmacology and psychobiology at the University of California San Diego and Stanford University.
1. Discuss the prevalence and consequences of nonadherence among patients with schizophrenia
2. Integrate evidence-based medical and non-medical interventions for improved schizophrenia treatment adherence into daily practice
3. Evaluate and interpret efficacy, safety, and outcomes data for LAI antipsychotics for schizophrenia
4. Select the most appropriate patients for LAI intervention
5. Institute discussions with patients that include incorporating LAIs as a potential management option

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Christoph U. Correll, MD, has affiliations with Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, MedAvante, Medscape, Pfizer, ProPhase, Otsuka, Roche, Sunovion, Supernus, Takeda (Consulting); Eli Lilly, Genentech, IntraCellular Therapies, Lundbeck, Medscape, Otsuka, Roche, and Sunovion (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); Bristol-Myers Squibb and Otsuka (Research).
  • John M. Kane, MD, has affiliations with Alkermes, Forrest, Genentech, Intracellular Therapeautics, Lundbeck, Otsuka, and Roche (Consulting); Invivo,  Janssen, Novartis, Reviva, and Targacept (Speaker).
  • John Lauriello, MD,​ has affiliations with Janssen and Sunovion (Research).
RMEI, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Nora Hartley, MLIS, has no affiliations with commercial interests relative to the content to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 0.75 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners and physician assistants are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians, nurse practitioners and physician assistants who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 80% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above